Compare RYTM & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | GNTX |
|---|---|---|
| Founded | 2008 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.0B |
| IPO Year | 2017 | 1995 |
| Metric | RYTM | GNTX |
|---|---|---|
| Price | $115.63 | $24.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 5 |
| Target Price | ★ $131.14 | $26.60 |
| AVG Volume (30 Days) | 640.7K | ★ 2.5M |
| Earning Date | 05-05-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ 1.00 |
| Revenue | N/A | ★ $2,534,268,965.00 |
| Revenue This Year | $55.34 | $6.89 |
| Revenue Next Year | $86.06 | $4.58 |
| P/E Ratio | ★ N/A | $23.54 |
| Revenue Growth | N/A | ★ 9.55 |
| 52 Week Low | $74.50 | $20.48 |
| 52 Week High | $122.20 | $29.38 |
| Indicator | RYTM | GNTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 45.43 |
| Support Level | $98.76 | $22.50 |
| Resistance Level | $113.03 | $24.03 |
| Average True Range (ATR) | 4.84 | 0.63 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 98.64 | 60.44 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.